Scribe Inks CRISPR Gene-Editing Deal with Prevail

CRISPR pioneer Jennifer Doudna’s company Scribe Therapeutics inked a major deal with Prevail Therapeutics potentially worth $1.5 billion to create genetic medicines for neurological and neuromuscular diseases. Scribe CEO Ben Oakes joins Caroline Hyde for more.

Scribe’s molecules can be “delivered via pretty much every delivery technology that currently exists,” said Oakes. The biotech has explored AAV delivery — being able to do single, double and triple-cut genome editing within a single vector — and lipid nanoparticles for the past four or so years. They’re also looking at other delivery modalities and are not yet “wedded” to a particular approach as the field rapidly evolves, he said.




Scribe Therapeutics



This is a unique website which will require a more modern browser to work!

Please upgrade today!